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A B S T R A C T
Background: Bone is a metastatic site for various types of cancer. Cancer patients in whom bone metastases
progress often have skeletal-related events (SREs). Denosumab and zoledronic acid are both bone-modifying
agents that prevent the occurrence of SREs. Denosumab has been shown to be superior to zoledronic acid in
delaying SREs in various types of cancer, such as breast cancer, lung cancer, and multiple myeloma. However, it
is still uncertain whether denosumab is superior to zoledronic acid in delaying the time to SREs in other types of
cancers, including gastrointestinal cancer, pancreas-biliary system cancer, and other rare cancers.
Patients and methods: This retrospective study was conducted based on medical records from 2009 to 2015.
Eligible patients who had been diagnosed with bone metastases from gastrointestinal cancer, pancreas-biliary
system cancer, and rare cancers were included. Patients were assigned to a denosumab group, zoledronic acid
group, or group without bone-modifying agent treatment (no-treatment group).
Results: The study included 168 patients. The times to SREs in the denosumab, zoledronic acid, and no-
treatment groups were 186 days [95% conﬁdence interval (CI), 96–323 days], 79 days (95% CI, 45–118 days),
and 31 days (95% CI, 13–76 days), respectively. Although, a few patients had grade 3 or 4 adverse events in the
denosumab and zoledronic acid groups, the bone-modifying agent treatment was not terminated.
Conclusion: From the perspective of the eﬃcacy and safety of denosumab for delaying the time to SREs,
denosumab should be used to prevent SREs in patients with bone metastases from gastrointestinal cancer,
pancreas-biliary system cancer, and other rare cancers.
1. Introduction
Bone is one of the metastatic sites for various types of cancer. It has
been reported that 5–25% of patients with gastrointestinal cancer and
pancreas-biliary system cancer suﬀer from bone metastases [1–4].
Patients with bone metastases frequently develop skeletal-related
events (SREs), which include pathologic fractures, spinal cord com-
pression, bone pain necessitating bone surgery or palliative radiation,
and hypercalcemia [5]. Once SREs occur in patients with bone
metastases, activities of daily life are restricted and quality of life is
deteriorates. Zoledronic acid and denosumab are two bone-modifying
agents that prevent SREs in patients with bone metastases.
Zoledronic acid is a third generation bisphosphonate that inhibits
farnesyl diphosphate synthase and reduces the post-translational
prenylation of proteins, such as small GTPases. This results in the
lowering of bone turnover followed the inhibition of the bone repara-
tive ability and also results in disruption of metabolic pathways that are
essential for cancer cell survival in various types of cancer [6,7].
Previous retrospective study reported that zoledronic acid can delay
the time to SREs in patients with bone metastases from colorectal
cancer when compared to the time to SREs in these without treatment
of zoledronic acid [8]. Denosumab is a fully human monoclonal
antibody, which binds to the receptor activator of nuclear factor
kappa-B ligand (RANKL) and inhibits osteoclast function and bone
resorption [9]. It had been reported that by three international,
randomized, phase 3 studies that subcutaneous administration of
denosumab signiﬁcantly delay the time to SREs than intravenous
administration of zoledronic acid in the patients with bone metastases
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from breast cancer, prostate cancer and non-small cell lung cancer,
multiple myeloma and other tumors [10–12]. Both these bone-
modifying agents are used parenterally to prevent SREs in patients
with bone metastases from various types of cancer. A few randomized
studies have shown that denosumab is superior to zoledronic acid for
delaying the time to SREs in patients with bone metastases from some
types of cancers. However, it is uncertain whether denosumab is
superior to zoledronic acid for delaying the time to SREs in patients
with bone metastasis from gastrointestinal cancer, including esopha-
geal cancer, gastric and colorectal cancer, and pancreas-biliary system
cancer and other rare cancers.
Because there are no previous studies comparing the potency of
denosumab and zoledronic acid on delaying the time to SREs in
gastrointestinal cancer, pancreas-biliary cancer, and other rare cancers,
investigation into which bone-modifying agent (denosumab or zole-
dronic acid) is more potent in delaying the time to SREs in patients
with these cancers is valuable. Therefore, we conducted a retrospective
study in our hospital to evaluate the eﬃcacy and safety of denosumab
and zoledronic acid in delaying the time to SREs in patients with bone
metastases from gastrointestinal cancer, pancreas-biliary system can-
cer, and other rare cancers.
2. Patients and methods
The medical records of patients who were diagnosed with bone
metastases from gastrointestinal cancer, pancreas-biliary system can-
cer, and other rare cancers, as conﬁrmed using plain radiography,
isotopic scintigraphy, computed tomography (CT) or magnetic reso-
nance imaging (MRI), from 2008 to 2015 were retrospectively
reviewed. Patients with histopathologically diagnosed cancers were
eligible. In eligible patients, zoledronic acid (4 mg/body weight) was
intravenously administered or denosumab (120 mg/body weight) was
subcutaneously administered once a month depend on physician's
choice. SREs were deﬁned as pathologic fractures, spinal cord com-
pression, bone pain necessitating bone surgery or palliative radiation,
and hypercalcemia. The time to SREs in patients with bone metastasis
was deﬁned as the time from diagnosis of bone metastases, as
conﬁrmed on imaging, to the ﬁrst occurrence of SREs. All statistical
analyses were performed using JMP® 11 (SAS Institute Inc., Cary, NC,
USA). All toxicities were reviewed in the medical records and evaluated
according to the Common Terminology Criteria for Adverse Events,
version 4.0 [13].
3. Results
3.1. Patient characteristics
We identiﬁed 168 patients who were diagnosed with bone metas-
tases on imaging. The patient characteristics are shown in Table 1.
Zoledronic acid was intravenously administered in 99 patients (zole-
dronic acid group) and denosumab was subcutaneously administered
in 50 patients (denosumab group). No bone-modifying agent was
administered in the remaining 19 patients (no-treatment group). The
reason why these patients were not treated any bone-modifying agent
was unclear from medical records. The ratio of patients with gastro-
intestinal cancer, including esophageal cancer, gastric cancer, and
colorectal cancer, was higher in each group. A few cases of rare cancers,
including sarcoma, neuroendocrine carcinoma, cancer of unknown
primary, melanoma, anal cancer, and adrenal cancer, were included
in the study subjects (Table 1). Denosumab has been used in our
laboratory from 2012 when it was approved in Japan. Therefore, there
were no patients who were treated with denosumab from 2009 to 2012.
3.2. Eﬃcacy
As a whole, denosumab was more eﬀective than zoledronic acid in
delaying the time to SREs in patients with bone metastases (Fig. 1).
The median SRE-free survival times in the denosumab, zoledronic acid,
and no-treatment groups were 186 days [95% conﬁdence interval (CI),
96–323 days], 79 days (95% CI, 45–118 days), and 31 days (95% CI,
13–76 days), respectively. The rates of patients without SREs in the
denosumab and zoledronic acid groups were signiﬁcantly higher than
those in the no-treatment group (Fig. 1). The number of patients
without SREs was signiﬁcantly higher in the denosumab group than
those in the zoledronic acid group (Fig. 1. p=0.0053).
In total, 117 out of 168 patients had SREs during the study period.
The ratios of patients who suﬀered from SREs in the zoledronic acid,
denosumab, and no-treatment groups were 67.7%, 60.0%, and 94.7%,
Table 1
Patient’s characteristics.
Zoledronic acid Denosmab No-treatment p-value
No 99 50 19
Sex
Female 21(21.2) 15(30.0) 3(15.8) 0.3496
Male 78(78.8) 35(70.0) 16(84.2)
Performance status
0 40(40.0) 18(36.0) 9(47.4) 0.6818
1 55(55.6) 30(60.0) 10(52.6) 0.8184
≧2 4(4.0) 2(4.0) 0(0.0) 0.6725
Cancer primary site
Esophagus 37(37.4) 16(32.0) 6(31.6) 0.7638
Stomach 22(22.2) 9(18.0) 3(15.8) 0.73
Colorectum 15(15.2) 14(28.0) 6(31.6) 0.0896
Pancreas-biliary
system
8(8.1) 3(6.0) 1(5.3) 0.8475
Sarcoma 3(3.0) 3(6.0) 2(10.5) 0.3303
Neuroendocrine
carcinoma
7(7.1) 3(6.0) 0(0.0) 0.4907
CUP 6(6.1) 1(2.0) 0(0.0) 0.3161
Melanoma 1(1.0) 0(0.0) 0(0.0) 0.7043
Anal 0(0.0) 1(2.0) 0(0.0) 0.3051
Adrenal 0(0.0) 0(0.0) 1(5.3) 0.1561
Month from initial
diagnosis of bone
metastases to start
administration of
bone-modifying
reagent
0.3 0.29 ‐
Bone metastatic type
Osteolytic 64(64.6) 29(58.0) 12(63.1) 0.7297
Osteoblastic 30(30.0) 17(34.0) 4(21.1) 0.8074
Mixed 5(5.1) 4(8.0) 3(15.8) 0.24
Site of bone metastases
Pelvis 31(31.3) 18(36.0) 5(26.3) 0.716
Spine 53(53.5) 25(50.0) 12(63.2) 0.6193
Femur 3(3.0) 2(4.0) 1(5.3) 0.8743
Sternum 1(1.0) 2(4.0) 1(5.3) 0.36
Skull 4(4.0) 1(2.0) 1(5.3) 0.7484
Rib 19(19.2) 13(26.0) 4(21.1) 0.6324
Number of metastases
1 76(76.8) 36(72.0) 14(73.7) 0.8096
2 13(13.1) 10(20.0) 4(21.1) 0.2587
≧3 10(10.1) 4(8.0) 1(5.3) 0.7656
Year of starting bone modifying agent
2009 13(13.1) 0(0.0) –
2010 18(18.2) 0(0.0) –
2011 11(11.1) 0(0.0) –
2012 12(12.1) 13(26.0) –
2013 27(27.3) 5(10.0) –
2014 10(10.1) 24(48.0) –
2015 8(8.1) 8(16.0) –
CUP: Cancer of unknown primary.
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respectively (Table 2). Radiation to bone was the most frequent SRE in
each group. Overall skeletal morbidity rate were 0.17, 0.15 and 0.24 in
zoledronic acid group, denosumab group and no-treatment group,
respectively.
The SRE-free time was further analyzed in the patients with
gastrointestinal cancer, including esophageal cancer, gastric cancer,
and colorectal cancer. In patients with esophageal cancer, the median
times to SREs in the denosumab, zoledronic acid, and no-treatment
groups were 105 days (95% CI, 50–567 days), 40 days (95% CI, 26–81
days), and 26 days (95% CI, 6–198 days), respectively (Fig. 2). In
patients with gastric cancer, the median times to SREs in the
denosumab, zoledronic acid, and no-treatment groups were 377 days
(95% CI, 63–457 days), 126 days (95% CI, 65–315 days), and 62 days
(95% CI, 32–201 days), respectively (Fig. 3). In patients with colorectal
cancer, the median times to SREs in the denosumab, zoledronic acid,
and no-treatment groups were 107.5 days (95% CI, 38–344 days), 83
days (95% CI, 7–169 days), and 26.5 days (95% CI, 11–119 days),
respectively (Fig. 4). For all three types of cancer, the proportion of
patients without SREs was signiﬁcantly higher in the denosumab group
compared with the no-treatment group, whereas there was no diﬀer-
ence in the proportion of patients without SREs between the zoledronic
acid and no-treatment groups.
3.3. Safety
The frequency of adverse events in each group is shown in Table 3.
The percentages of patients with grade 3 or 4 increase in serum
creatinine were 4.0%, 6.1%, and 0% in the denosumab, zoledronic acid,
and no-treatment groups, respectively. The percentages of patients
with grade 3 or 4 hypocalcemia were 8.0%, 2.0%, and 0% in the
denosumab, zoledronic acid, and no-treatment groups, respectively.
There were no patients with osteonecrosis of the jaw in this study.
4. Discussion
In the present study, denosumab demonstrated a statistically
signiﬁcant superiority over zoledronic acid in delaying the time to
SREs in all the subjects (Fig. 1). This was consistent with previous
reports [10–12,14]. However, our study showed the diﬀerence between
the two drugs in cancers that have not been reported so far. (Previous
report by Henry et al. contained approximately 900 patients with bone
metastases from ‘other’ primary tumor. However, how many number of
patients with gastrointestinal system cancer, pancreas-biliary system
cancer or rare cancer were contained in these ‘other’ primary tumor
was unclear.) As shown in Fig. 2, denosumab was superior to
Fig. 1. Kaplan-Meier estimates of time to skeletal-related events (SREs) of all the
groups.
Table 2
Percentage of patients with SREs and type of SREs.
Zoledronic acid
(n=99)
Denosumab
(n=50)
No-treatment
(n=19)
Number of patients
with SREs
67(67.7) 30(60.0) 18(94.7)
Radiation to bone 43(43.4) 18(36.0) 13(68.4)
Pathological fracture 2(2.0) 3(6.0) 0(0.0)
Spinal cord
compression
18(18.2) 8(16.0) 4(21.1)
Surgery to bone 0(0.0) 0(0.0) 0(0.0)
Hyper calcemia 4(4.0) 1(2.0) 1(5.3)
Fig. 2. Kaplan-Meier estimates of time to skeletal-related events (SREs) in patients with
esophageal cancer.
Fig. 3. Kaplan-Meier estimates of time to skeletal-related events (SREs) in patients with
gastric cancer.
Fig. 4. Kaplan-Meier estimates of time to skeletal-related events (SREs) in patients with
colorectal cancer.
Table 3
Adverse events in patients of each group.
Grade3/4 adverse
events
Zoledronic
acid (n=99)
Denosumab
(n=50)
p-value
(Deno vs
Zol)
No-treatment
(n=19)
Increased serum
Creatinine
6(6.1) 2(4.0) 0.7183 0(0.0)
Hypocalcemia 2(2.0) 4(8.0) 0.0978 0(0.0)
AST/ALT elevated 3(3.0) 2(4.0) 0.5458 1(5.3)
Arthralgia 3(3.0) 2(4.0) 0.5458 0(0.0)
Fatigue 8(8.1) 5(10.0) 0.4551 1(5.3)
Nausea 7(7.1) 3(6.0) 0.553 2(10.5)
Osteonecrosis of
the jaw
0(0.0) 0(0.0) 1 0(0.0)
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zoledronic acid in delaying the time to SREs in patients with
esophageal cancer. In patients with bone metastases from gastric
cancer and colorectal cancer, the rate of patients without SREs in the
denosumab group was signiﬁcantly higher than in the no-treatment
group (Figs. 3, 4). Denosumab but not zoledronic-acid signiﬁcantly
delayed the median time to SREs in patients with gastric cancer and
colorectal cancer when compared to the no-treatment group.
Therefore, denosumab was superior to zoledronic acid in delaying the
time to SREs not only in patients with esophageal cancer but also in
patients with gastric cancer and colorectal cancer.
The frequency of toxicities with denosumab and zoledronic acid
were similar (Table 3). However, in this study, the frequency of
hypocalcemia with denosumab was higher than with zoledronic acid,
similar to several previous prospective studies [10–12,14]. In the
present study, no bone-modifying treatment was terminated due to
severe adverse events, indicating that both denosumab and zoledronic
acid were tolerated by the patients with bone metastases from
gastrointestinal cancer, pancreas-biliary system cancer, and other rare
cancers.
In the present study, before 2011, no patients were treated with
denosumab. The percentage of patients treated with denosumab
increased dramatically from 2014. The higher proportion of SRE-free
patients in the denosmab group may be mediated by the introduction
of newly developed anticancer agents, such as regorafenib and triﬂur-
idine-tipiracil hydrochloride, which are approved for colorectal cancer,
and trastuzumab and ramucirumab, which are approved for gastric
cancer, from 2009 to 2015. However, in the present study, only two out
of 35 colorectal cancer patients were treated with regorafenib, only one
out of 35 patients with colorectal cancer was treated with triﬂuridine-
tipiracil hydrochloride, only one out of 34 patients with gastric cancer
was treated with trastuzumab, and only one out of 34 patients with
gastric cancer was treated with ramucirumab during bone-modifying
agent therapy. No new anticancer agent was developed for advanced
esophageal cancer from 2009 to 2015. Therefore, the prolongation of
the time to SREs in esophageal cancer, gastric cancer, and colorectal
cancer were brought about by the eﬀect of denosumab and not by other
anticancer agents.
Limitations of the present study include the small number of
eligible patients in each group and the retrospective design of the
study. Although, the frequency of bone metastasis in hepatocellular
carcinoma has been reported to be similar to that in esophageal cancer,
gastric cancer, and colorectal cancer [15], no patient with hepatocel-
lular carcinoma was included in the present study. Further study on the
eﬀect of denosumab and zoledronic acid on SREs in patients with bone
metastases from hepatocellular carcinoma is warranted.
From the results of the present study, it can be concluded that
denosumab is superior to zoledronic acid in delaying the time to SREs
in patients with bone metastases from gastrointestinal cancer, pan-
creas-biliary cancer, and other rare cancers. This is similar to previous
studies in patients with breast cancer [10], prostate cancer [11], lung
cancer, multiple myeloma [12], renal cancer, and urinary bladder
cancer [14]. The results from our study and previous reports suggest
that denosumab should be used preferentially in patients with bone
metastases from various types of cancer.
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